All adverse events · people with inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
All adverse events · people without inhibitors
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
All adverse events · people with inhibitors
Summary of findings table ‐ Emicizumab prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
1 finding from 1 review
Adverse effects (drop‐outs due to adverse effects4) · patients with restless legs syndrome
Summary of findings: levodopa probably leads to lower number of drop outs due to adverse events compared with other dopamine agonists (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
It is very uncertain whether summary of findings ‐ nebulisers for delivering tobramycin:… changes adverse events compared with VMT (very low certainty).
1 finding from 1 review
Adverse events · children aged 6 ‐ 18 with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Adverse events · children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Frequency of adverse events ( · children with haematological malignancy at risk of tumour lysis syndrome
Summary of findings: urate oxidase may leads to higher frequency of adverse events ( compared with allopurinol (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
1 finding from 1 review
Adverse events · health problem or population
1 finding from 1 review
Adverse events At final · individuals with an investigator‐reported diagnosis of Achilles tendinopathy (or related terminology, e.g. tendinitis). We excluded trials…
It is very uncertain whether summary of findings: Injection therapies changes adverse events At final compared with placebo or no injection control (very low certainty).
1 finding from 1 review
Adverse events · adults with cystic fibrosis and either F508del/MF or F508del/F508del genotype
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Adverse events: all grades · individuals with moderate to severe disease
It is very uncertain whether summary of Findings Table ‐ Vitamin D changes adverse events (any grade) compared with placebo or standard care alone (very low certainty).
1 finding from 1 review
Serious adverse events · children with respiratory syncytial virus infection
Summary of findings table ‐ Immunoglobulins showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review